An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RxSight, Inc., a medical device company specializing in customized vision after cataract surgery, will be presenting at the Bank of America Healthcare Conference on May 15, 2024. The presentation will be available for viewing online.
RxSight, Inc., un'azienda di dispositivi medici specializzata nella personalizzazione della vista dopo l'intervento di cataratta, si presenterà alla conferenza sanitaria della Bank of America il 15 maggio 2024. La presentazione sarà disponibile per la visione online.
RxSight, Inc., una empresa de dispositivos médicos especializada en la visión personalizada después de la cirugía de cataratas, presentará en la Conferencia de Salud de Bank of America el 15 de mayo de 2024. La presentación estará disponible para ver en línea.
백내장 수술 후 맞춤 시력을 전문으로 하는 의료 기기 회사인 RxSight, Inc.가 2024년 5월 15일에 Bank of America 헬스케어 컨퍼런스에서 발표할 예정입니다. 이 발표는 온라인으로 시청할 수 있습니다.
RxSight, Inc., une entreprise de dispositifs médicaux spécialisée dans la vision personnalisée après une chirurgie de la cataracte, présentera lors de la Conférence sur la santé de Bank of America le 15 mai 2024. La présentation sera disponible en ligne.
RxSight, Inc., ein Medizinprodukteunternehmen, das auf individuell angepasste Sehlösungen nach Kataraktoperationen spezialisiert ist, wird am 15. Mai 2024 auf der Bank of America Healthcare Konferenz präsentieren. Die Präsentation wird online verfügbar sein.
Positive
None.
Negative
None.
ALISO VIEJO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.
RxSight’s management is scheduled to present on Wednesday, May 15, 2024, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+™), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact: Shelley B. Thunen Chief Financial Officer sthunen@rxsight.com
Investor Relations Contact: Oliver Moravcevic VP, Investor Relations omoravcevic@rxsight.com
FAQ
When will RxSight, Inc. present at the Bank of America Healthcare Conference?
RxSight, Inc. will present on Wednesday, May 15, 2024, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time.
Where can interested parties access the live and archived webcast of the presentation?
Interested parties can access the webcast at https://investors.rxsight.com/.
calhoun vision is the world leader in adjustable intraocular lens technology. the company's proprietary technology utilizes light to enable surgeons to change the power of a lens after it has been implanted in the eye. this offers the potential to provide unparalleled visual outcomes and customization to the specific visual needs of each patient. calhoun vision's light adjustable lens technology is an investigational device in the united states and requires fda approval before it can be marketed commercially. the company has completed phases i and ii of the required clinical investigation; the third and final phase of study has commenced, and all subjects have been fully enrolled.
